Nav: Home

Cutting the time on early disease diagnoses with extracellular vesicles

May 20, 2019

When an individual has cancer, or any number of other diseases, early detection can make a huge difference in the outcome. A research team led by the University of Notre Dame is working to cut the test time for disease biomarkers. The new timeline -- 30 minutes instead of 13 hours -- uses even smaller sample sizes to offer a new liquid biopsy option.

The difference is an integrated microfluidics platform developed at Notre Dame that uses extracellular vesicles (EVs) containing microRNAs (miRNAs) as biomarkers for early-stage disease diagnosis.

"Extracellular vesicles contribute to intercellular communication, especially during specific cellular processes such as coagulation or immune responses," said Hsueh-Chia Chang, co-lead of the study and Bayer Professor of Chemical and Biomolecular Engineering at Notre Dame. "More importantly, we are just now learning that EVs and the microRNA they carry also play a role in disease proliferation. If we can detect them accurately, quickly and cost-effectively, they could very well be the key to early cancer detection."

Cells secrete EVs, which are easily isolated in bodily fluids such as blood, saliva and even breastmilk.

Chang's team developed a viable screening tool that significantly improves the inefficiencies of more conventional methods of EV-miRNA analysis.

"What we've developed is essentially a microfluidic chip that takes a small amount of blood plasma and analyzes it for a target EV microRNA in about 30 minutes," said David Go, Rooney Family Associate Professor of Engineering at Notre Dame and a co-lead on the study. "By using a mechanical piezoelectric device to break open the EVs and an electrical device to detect the microRNA, we remove all the inefficiencies associated with purification, extraction and RNA detection using PCR-based approaches -- and it's a lot faster."

The study, published in Nature Communications Biology, details the screening tool and its performance. The Notre Dame team worked with cancer researchers from the University of Southern California, including Reginald Hill, assistant professor of medicine at the Keck School of Medicine and the Lawrence J. Ellison Institute for Transformative Medicine, and Bangyan Stiles, professor in the USC School of Pharmacy, to test the new device with both human and mouse liver cancer samples, demonstrating its clinical potential.

One of the most exciting aspects of the device is that it can be easily extended for other RNA and DNA biomarkers and potentially even proteins. The Notre Dame team has already started exploring other early-detection challenges such as preeclampsia and pancreatic cancer. As they continue to develop the technology, the team aims to offer the first liquid biopsy diagnostic device that is simple, rapid, user-friendly and capable of detecting biomarkers from clinical samples as early in the disease process as possible.

"Such a device could profoundly change how we approach health care and, more importantly, provide a better quality of life," Chang said. "We believe we are well on our way."
Co-authors on the study include Satyajyoti Senapati, research assistant professor of chemical and biomolecular engineering; Zeinab Ramshani, a postdoctoral researcher in chemical and biomolecular engineering; and Chenguang Zhang, engineering graduate student, all at Notre Dame.

The National Institutes of Health, C. Moschetto Discovery Fund and Notre Dame's Advanced Diagnostics and Therapeutics initiative funded the study in collaboration with the Center for Microfluidics and Medical Diagnostics at Notre Dame and the Harper Cancer Research Institute.

University of Notre Dame

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 2: Every Day is Ignaz Semmelweis Day
It began with a tweet: "EVERY DAY IS IGNAZ SEMMELWEIS DAY." Carl Zimmer – tweet author, acclaimed science writer and friend of the show – tells the story of a mysterious, deadly illness that struck 19th century Vienna, and the ill-fated hero who uncovered its cure ... and gave us our best weapon (so far) against the current global pandemic. This episode was reported and produced with help from Bethel Habte and Latif Nasser. Support Radiolab today at